All In Biotech

NDA 013025 · Hospira

Tham

Tromethamine, Potassium Chloride, Sodium Chloride · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 8, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1965

Dec 16, 1965

Approved uses

1

Original approval plus efficacy supplements

Registered trials

380

73 Phase 3, 25 recruiting

FAERS reports

179

109 serious, 14 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 27, 2026.

INDICATIONS AND USAGE Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 16, 1965 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review
2 products under this application
  • THAM · TROMETHAMINE 18GM/500ML (3.6GM/100ML) · SOLUTION, INJECTION · Prescription · TE AP
  • THAM-E · POTASSIUM CHLORIDE 370MG/VIAL; SODIUM CHLORIDE 1.75GM/VIAL; TROMETHAMINE 36GM/VIAL · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Tromethamine" as an intervention, any sponsor and status, largest first.

All 380 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea23
  • urinary tract infection22
  • drug ineffective18
  • headache18
  • pain17
  • fall16
  • off label use16
  • vomiting15
  • diarrhoea14
  • fatigue14
  • drug interaction11
  • product dose omission issue11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20061
20081
20092
20112
20122
20132
20145
20156
20168
201712
20188
201913
202026
202113
202212
202325
202417
202517
20265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 363 on PubMed

Sponsor: Pfizer · Also marketed as Tham-E

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.